Fundraising Fox
iFAST
Whiteley, GB · Founded 2022 · 27 employees on LinkedIn · 8 known investors
Find your way into iFAST
Sign up to see every warm intro you have to iFAST
- Paths you didn't know you had: your email and LinkedIn already hold routes to the iFAST team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
iFAST Diagnostics develops rapid antimicrobial susceptibility testing (AST) technology that delivers susceptibility test results in under 3 hours, significantly faster than the standard 40-hour process. The company serves clinical laboratories and hospitals to help combat antimicrobial resistance.
Founders & leadership
Investors · 8
How we know: the company's own site · funding news · 360dx.com · Not right? Tell us
How we know: the company's own site · press coverage · Not right? Tell us
How we know: the company's own site · 360dx.com · Not right? Tell us
How we know: Future Planet Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 2
Funding
SEC filings, press & company announcements- Undisclosed amountshare placementJan 2022Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Related companies · 2
Companies working in the same space as iFAST.
Companies House · registry record
View on Companies House ↗- Registered name
- IFAST UK HOLDINGS LIMITED
- Company number
- 13045848
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 26 Nov 2020
- Registered office
- 66 Lincoln's Inn Fields, London, WC2A 3LH
- Nature of business (SIC)
- 64205 — Activities of financial services holding companies
- Previous names
- EAGLES PEAK HOLDINGS LIMITED (2020–2024)
- Accounts
- last made up to 31 Dec 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 12 Sept 2025 · next due 26 Sept 2026
Current officers · 3
- Chung Chun Lim — director, appointed 3 Oct 2022
- Vincent Tong — director, appointed 6 Jan 2022
- Wong Weiyi — director, appointed 11 Apr 2023
Source: Companies House public register · retrieved 9 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does iFAST do?
- iFAST Diagnostics develops rapid antimicrobial susceptibility testing (AST) technology that delivers susceptibility test results in under 3 hours, significantly faster than the standard 40-hour process. The company serves clinical laboratories and hospitals to help combat antimicrobial resistance.
- Who are iFAST's investors?
- iFAST's investors include Meridian Health Ventures, Cambridge Capital Group, Innovate UK, Raw Ventures, Future Planet Capital, UK Innovation & Science Seed Fund.
- Where is iFAST headquartered?
- iFAST is headquartered in Whiteley, GB.